Valuation of Child Health-Related Quality of Life in the United States

from Health Economics at http://bit.ly/1IlP0Um on April 29, 2015 at 05:41AM Many economic analyses fail to incorporate evidence on child health-related quality of life because of a paucity of quality-adjusted life year (QALY) estimates. This health valuation study is the first to summarize the EQ-5D-Y on a QALY scale. Drawn from a nationally representative panel, […]

Health in Baltimore

from Healthcare Economist at http://bit.ly/1AebIqw on April 29, 2015 at 04:22AM Baltimore is in the news, and not for the best reasons.  The arrest and eventual death of Freddie Gray have unleashed a series of protests and riots.  One conference where the Healthcare Economist had a poster presentation–the American Heart Association (AHA) Quality of Care and […]

2015 OHE Annual Lecture: Regulation, Reimbursement, and Evidence on New Medical Technologies: Experiences and Future Directions in the United States

from News at http://bit.ly/1GDLaXk on April 28, 2015 at 11:27AM 2015 OHE Annual Lecture: Regulation, Reimbursement, and Evidence on New Medical Technologies: Experiences and Future Directions in the United States Tuesday, 28 April 2015 OHE announces their annual lecture for 2015. Dr Mark McClellan will present on 6 July on the topic of Regulation, Reimbursement, […]

2015 OHE Annual Lecture: Regulation, Reimbursement, and Evidence on New Medical Technologies: Experiences and Future Directions in the United States

from News at http://bit.ly/1GDLaXk on April 28, 2015 at 11:27AM 2015 OHE Annual Lecture: Regulation, Reimbursement, and Evidence on New Medical Technologies: Experiences and Future Directions in the United States Tuesday, 28 April 2015 OHE announces their annual lecture for 2015. Dr Mark McClellan will present on 6 July on the topic of Regulation, Reimbursement, […]

2015 OHE ANNUAL LECTURE: Regulation, Reimbursement, and Evidence on New Medical Technologies: Experiences and Future Directions in the United States

from News at http://bit.ly/1GDLaXk on April 28, 2015 at 11:27AM 2015 OHE ANNUAL LECTURE: Regulation, Reimbursement, and Evidence on New Medical Technologies: Experiences and Future Directions in the United States Tuesday, 28 April 2015 OHE announces their annual lecture for 2015. Dr Mark McClellan will present on 6 July on the topic of Regulation, Reimbursement, […]

Why legislative proposals to improve drug and device development must look beyond FDA approvals

from Brookings Topics – Health at http://brook.gs/1do82Oa on April 28, 2015 at 01:00PM Legislative proposals to accelerate and improve the development of innovative drugs and medical devices generally focus on reforming the clinical development and regulatory review processes that occur before a product gets to market. Many of these proposals – such as boosting federal […]

Faster, more efficient innovation through better evidence on real-world safety and effectiveness

from Brookings Topics – Health at http://brook.gs/1GBqQmF on April 28, 2015 at 05:00AM Many proposals to accelerate and improve medical product innovation and regulation focus on reforming the product development and regulatory review processes that occur before drugs and devices get to market. While important, such proposals alone do not fully recognize the broader opportunities […]

Why legislative proposals to improve drug and device development must look beyond FDA approvals

from Brookings Topics – Health at http://brook.gs/1do82Oa on April 28, 2015 at 01:00PM Legislative proposals to accelerate and improve the development of innovative drugs and medical devices generally focus on reforming the clinical development and regulatory review processes that occur before a product gets to market. Many of these proposals – such as boosting federal […]

Faster, more efficient innovation through better evidence on real-world safety and effectiveness

from Brookings Topics – Health at http://brook.gs/1GBqQmF on April 28, 2015 at 05:00AM Many proposals to accelerate and improve medical product innovation and regulation focus on reforming the product development and regulatory review processes that occur before drugs and devices get to market. While important, such proposals alone do not fully recognize the broader opportunities […]